CTOs on the Move

OncoHealth

www.oncohealth.us

 
OncoHealth is a leading digital health company dedicated to helping health plans, employers, providers, patients and life science researchers navigate the physical, mental and financial complexities of cancer through technology enabled services and real-world data analytics. Supporting more than 7 million people in the US and Puerto Rico, OncoHealth offers digital solutions for treatment review, real-world evidence, and virtual care across all cancer types.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.oncohealth.us
  • 7000 Central Parkway Suite 1750
    Atlanta, GA USA 30328
  • Phone: 888.916.2616

Executives

Name Title Contact Details
Susan Hoang
Chief Data and Analytics Officer Profile
Robert Maddrey
Director, Information Technology and Cybersecurity Profile

Funding

OncoHealth raised $21M on 11/05/2018
OncoHealth raised $28M on 05/26/2020

Similar Companies

Avid Radiopharmaceuticals Inc

Avid Radiopharmaceuticals Inc is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Programable Devices Inc

Programable Devices Inc is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quality Packaging L L C

Quality Packaging L L C is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Burlington, NJ. To find more information about Quality Packaging L L C, please visit www.qpsiusa.com

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.

WESTLAKE Financial Group

We support human resource departments and organizational workforces. From HR and benefits consulting services to health plan network management to benefits administration functions and processes, we support each and every aspect of a company's benefit